Streetbeat News

Partnerships

EVO

Shares of Evotec SE (EVO) are down in premarket trading after the announcement that CEO Werner Lanthaler is stepping down for personal reasons. Despite this, Evotec confirmed its 2023 revenue guidance of €750-790 million. Additionally, Evotec has entered into an AI-powered multi-target collaboration with Owkin, focusing on oncology, immunology, and inflammation. This partnership will leverage Owkin's AI for target discovery and Evotec's R&D platform, with Evotec receiving R&D funding, potential milestone payments, and royalties from Owkin.

Portfolio Pulse from Nabaparna Bhattacharya

January 04, 2024 | 12:11 pm

LE

Lands' End has launched an exclusive women's swimwear collection featuring nearly 70 pieces, which will be available for purchase at Target stores.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:55 am

GIB

CGI, also known as GIB on the NYSE, has been chosen by NATS, the UK's air traffic control service, to assist in transforming its digital infrastructure. This partnership aims to modernize the technological framework that supports air traffic management in the UK.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:32 am

FSLR

First Solar, Inc. has signed a 15-year Power Purchase Agreement (PPA) with Cleantech Solar, a leading provider of renewable energy solutions in India and Southeast Asia. This agreement will enable First Solar to supply solar power to Cleantech Solar's customers in the region, reinforcing First Solar's presence and commitment to the renewable energy market in Asia.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:04 am

TNGX

Medivir AB announced that its licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor for treating various HRD+ cancers. The FDA cleared the Investigational New Drug application for TNG348 in September 2023. TNG348 targets up to 50% of ovarian, 25% of breast, 10% of prostate, and 5% of pancreatic cancers with HRD+ including BRCA1/2 mutations. Tango is developing TNG348 based on a preclinical USP1 program licensed from Medivir in 2020.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:59 am

FFIE

Faraday Future (FFIE) hosted a delegation of Chinese automotive suppliers at its LA headquarters to discuss cooperation opportunities. The meeting included representatives from Shanghai Yida Air Conditioning, Shanghai Suce Software, Lucky Yundu Auto, Zhi Xing Automotive Technology, and Kunshan Guoli Yuantong New Energy Technology. The discussions focused on smart electric vehicle supply chains to China.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:20 am

JNPR

Juniper Networks has implemented its AI-driven wireless solutions at National Chi Nan University (NCNU), enhancing the networking experience for students and staff and fostering a transformative learning environment.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:10 am

PPIH

Perma-Pipe International (PPIH) has been accepted into QatarEnergy's Tawteen Program, which focuses on supply chain localization for Qatar's energy sector. PPIH will provide pre-insulated piping systems, custom fabrication, and 3-layer polyethylene coatings for QatarEnergy projects.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 6:40 am

CELU

BioCellgraft has entered into a commercialization agreement with Celularity (CELU) to manufacture and distribute products for therapeutic use in oral healthcare. BioCellgraft will market these products under private label brand names, which will be announced in early 2024. The products include treatments for soft tissue defects and serve as barrier membranes in various dental applications. The collaboration aims to meet unmet needs in oral healthcare by combining BioCellgraft's expertise in dentistry with Celularity's placental-derived biomaterial technology.

Portfolio Pulse from Charles Gross

January 03, 2024 | 10:22 pm

ABBV

CVS

AbbVie has signed an agreement to supply Cordavis, a CVS Health subsidiary, with a committed volume of co-branded Humira.

Portfolio Pulse from Charles Gross

January 03, 2024 | 10:06 pm